ArticleBlood vessels, thrombosis & hemostasis2026
Augmenting hemopexin-mediated heme scavenging mitigates sepsis-induced acute kidney injury in humanized sickle cell mice.
Article in Blood vessels, thrombosis & hemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Sickle cell disease (SCD) is characterized by chronic intravascular hemolysis and depletion of the heme scavenger hemopexin (HPX), generating a high-heme milieu that may increase susceptibility to inflammatory organ injury. Sepsis is a leading cause of acute kidney injury (AKI), yet the contribution of hemolysis-derived free heme to polymicrobial sepsis-associated AKI in SCD remains poorly defined. Using humanized SCD mice, we tested whether augmenting heme clearance via HPX mitigates septic AKI. Low-grade cecal ligation and puncture induced exaggerated systemic inflammation, elevated circulating heme and ferritin, and marked reductions in glomerular filtration rate (GFR) in sickling (hemoglobin SS [HbSS]) mice compared with nonsickling (HbAA) control mice. Septic SS mice also exhibited enhanced renal nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome activation, increased oxidative stress, and tubular injury, consistent with heme-driven inflammatory and cytotoxic signaling. Acute administration of purified human HPX reduced circulating heme and ferritin, attenuated cytokine responses, and preserved GFR, indicating that restoration of heme buffering in SCD interrupts kidney injury pathways during septic stress. To achieve sustained heme control, we restored HPX expression using liver-directed delivery of adeno-associated virus serotype 8 (AAV8). AAV8-HPX restored hepatic HPX, reduced basal and sepsis-induced plasma heme levels, conferred protection against kidney dysfunction and tubular stress, and improved survival without evidence of hepatotoxicity. Collectively, these findings identify free heme as a central mediator linking hemolysis to sepsis-associated AKI in SCD, and establish that HPX augmentation via protein replacement or gene therapy is a mechanistically targeted, potentially translatable therapeutic strategy to mitigate heme-driven tissue injury and improve outcomes in SCD-associated sepsis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.